Loading
A phase 1/2 trial of Fludarabine in her2-positive breast cancer and triple-negative breast cancer, run by Beijing Biotech, now recruiting.
Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC) is a phase 1/2 interventional study registered as NCT07486089 by Beijing Biotech, with 60 participants planned, started 2026-02-02 and due to reach its primary completion in 2027-02-14. Interventions recorded: Dual-target CAR-NK cells (EB-DT-CAR-NK), Lymphodepleting chemotherapy, Supportive care. Conditions listed: Breast Cancer (Locally Advanced or Metastatic), HER2-positive Breast Cancer, Triple-Negative Breast Cancer (TNBC). No results are recorded here; the registry entry is the source.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC), Cytotoxic chemotherapy.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC), Cytotoxic chemotherapy.
Shares Metastatic triple-negative breast cancer, HER2-positive breast cancer, Triple-negative breast cancer (TNBC).
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC), Cytotoxic chemotherapy.
Shares Fludarabine, Cytotoxic chemotherapy.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC).
Shares Fludarabine, Cytotoxic chemotherapy.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC).